{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:34:53Z","timestamp":1793309693422,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breast cancer is the most common cancer in women. Radiotherapy is an important part of breast cancer treatment after surgery. Breast cancer radiotherapy is usually delivered in 3\u20135 weeks. This is a long duration for women with breast cancer to stay away from the family and work. We wanted to reduce this duration so that the wages loss and the logistics can be minimised for these patients. Hypofractionation, i.e. high dose per fraction, is delivered in a smaller number of days. In this study, we will compare a 1-week schedule of hypofractionated adjuvant whole breast\/chest wall and\/or regional nodal radiotherapy against 2 weeks for locoregional disease control, toxicities, quality of life (QoL), survival and second cancers after primary surgery in patients with breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible patients with breast cancer after mastectomy or breast conserving surgery (BCS) will be treated with a radiotherapy dose of 26 Gy in 5 fractions over 1 week in the study arm and 34 Gy in 10 fractions over 2 weeks in the control arm. The primary endpoint of this noninferiority study will be locoregional tumour control. Secondary endpoints will be early and late radiation toxicities, quality of life, contralateral primary tumours, regional and distant metastases, survival and second cancers. A total of 1018 patients will be randomised (1:1) to receive 1 week or 2 weeks of radiotherapy. An event-driven analysis will be performed after at least 94 patients have documented locoregional recurrences. Acute radiation toxicity will be assessed and scaled according to the RTOG grading system. Late radiation toxicity will be assessed with the Radiation Therapy Oncology Group and the European Organisation for Research and Treatment of Cancer late radiation morbidity scale. Cosmetic assessment will be done using Harvard\/NSABP\/RTOG breast cosmesis grading scale at baseline and 3 and 5 years. QoL will be assessed with EORTC QLQ-30 and EORTC QLQ-BR 23 at baseline and 3 and 5 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Hypofractionation reduces treatment time to half while maintaining breast cosmesis and gives control rates equal to conventional fractionation. This is possible because breast tissue can tolerate high dose per fraction. In this study, we presume that 1-week radiotherapy will be non-inferior to 2 week radiotherapy, i.e. disease control will be similar with both the schedules without additional side effects, and QoL of these patients will be maintained. If we are able to achieve these outcomes, then patients will be able to complete their radiotherapy in less duration. There is not much data on regional nodal irradiation with hypofraction in breast cancer. We have used hypofraction for regional nodal irradiation in the past and not encountered any safety issue. If we are able to prove that late-term effects are comparable in the two schedules, it will make the radiation oncologist confident about hypofractionation in breast cancer. As breast cancer is a leading cancer in females and radiation therapy is an integral part of its local management, hypofractionation will help radiation centres worldwide to meet the growing need for radiation treatment in breast cancer, particularly in developing countries where resources are limited. It will also reduce the financial burden on the patient and family. Since we will treat these patients with both simple and complex radiotherapy techniques, it will also be possible for the low-income countries to follow this trial without needing a high-end or expensive radiotherapy equipment as the planning and treatment process will be very simple.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The trial is registered with ClinicalTrials.gov ID NCT04472845 and CTRI with REF\/2020\/09\/037050.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-023-07851-7","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T14:02:58Z","timestamp":1704204178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6185-4139","authenticated-orcid":false,"given":"Budhi Singh","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Dahiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishita","family":"Laroiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhosh","family":"Irrinki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngangom Robert","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"issue":"4","key":"7851_CR1","first-page":"218","volume":"3","author":"BS Yadav","year":"2008","unstructured":"Yadav BS, Sharma SC, Singh R, Singh G, Kumar V. Postmastectomy radiation and survival in patients with breast cancer. J Cancer Res Ther. 2008;3(4):218\u201324.","journal-title":"J Cancer Res Ther"},{"key":"7851_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1017\/S1460396915000278","volume":"14","author":"BS Yadav","year":"2015","unstructured":"Yadav BS, Sharma SC, Ghoshal S, Kapoor R, Kumar N. Outcome following postmastectomy internal mammary node radiation in patients with breast cancer-a long term follow up study. JRP. 2015;14:385\u201393.","journal-title":"JRP"},{"issue":"2","key":"7851_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4103\/0973-1482.34683","volume":"3","author":"BS Yadav","year":"2007","unstructured":"Yadav BS, Sharma SC, Patel FD, et al. Patterns of relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. J Cancer Res Ther. 2007;3(2):75\u201380.","journal-title":"J Cancer Res Ther"},{"key":"7851_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3857\/roj.2020.00129","volume":"38","author":"BS Yadav","year":"2020","unstructured":"Yadav BS, Bansal A, Kuttikat PG, Das D, et al. Late-term effects of hypofractionated chest wall and regional nodal radiotherapy with two-dimensional technique in patients with breast cancer. Radiat Oncol J. 2020;38:109\u201318.","journal-title":"Radiat Oncol J"},{"issue":"6","key":"7851_CR5","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1097\/IGC.0000000000000993","volume":"27","author":"BS Yadav","year":"2017","unstructured":"Yadav BS, Sharma SC, Patel FD, Rai B, Ghoshal S. Gynecological cancer as a second malignancy in patients with breast cancer. Int J Gynecol Cancer. 2017;27(6):1298\u2013304. https:\/\/doi.org\/10.1097\/IGC.0000000000000993. PMID: 28562469","journal-title":"Int J Gynecol Cancer"},{"key":"7851_CR6","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.4103\/jcrt.JCRT_549_19","volume":"16","author":"BS Yadav","year":"2020","unstructured":"Yadav BS, Sharma SC, Singh G, Dahiya D. Comparison of two radiation boost schedules in postlumpectomy patients with breast cancer. J Cancer Res Ther. 2020;16:1344\u20139.","journal-title":"J Cancer Res Ther"},{"issue":"4","key":"7851_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S1470-2045(08)70077-9","volume":"9","author":"The START Trialists\u2019 Group","year":"2008","unstructured":"The START Trialists\u2019 Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9(4):331\u201341; published online March 19. https:\/\/doi.org\/10.1016\/S1470-2045(08)70077-9.","journal-title":"Lancet Oncol"},{"issue":"9618","key":"7851_CR8","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S0140-6736(08)60348-7","volume":"371","author":"The START Trialists\u2019 Group","year":"2008","unstructured":"The START Trialists\u2019 Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098\u2013107; published online March 19. https:\/\/doi.org\/10.1016\/S0140-6736(08)60348-7.","journal-title":"Lancet"},{"key":"7851_CR9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S1470-2045(18)30813-1","volume":"20","author":"SL Wang","year":"2019","unstructured":"Wang SL, Fang H, Song YW, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2019;20:352\u201360.","journal-title":"Lancet Oncol"},{"issue":"2","key":"7851_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3857\/roj.2021.01053","volume":"40","author":"BS Yadav","year":"2022","unstructured":"Yadav BS, Gupta S, Dahiya D, Gupta A, Oinam AS. Accelerated hypofractionated breast radiotherapy with simultaneous integrated boost: a feasibility study. Radiat Oncol J. 2022;40(2):127\u201340. https:\/\/doi.org\/10.3857\/roj.2021.01053. Epub 2022 Jun 20. PMID: 35796116; PMCID: PMC9262700","journal-title":"Radiat Oncol J"},{"key":"7851_CR11","first-page":"503","volume":"26","author":"BS Yadav","year":"2021","unstructured":"Yadav BS, Dahiya D, Gupta A, et al. Breast cancer hypofractionated radiotherapy in 2-weeks with 2D technique: 5-year clinical outcomes of a phase 2 trial. Rep Pract Oncol Radiother. 2021;26:503\u201311.","journal-title":"Rep Pract Oncol Radiother"},{"issue":"4","key":"7851_CR12","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.ijrobp.2017.12.015","volume":"100","author":"BS Yadav","year":"2018","unstructured":"Yadav BS, Sharma SC. A phase II study of 2 weeks of adjuvant whole breast\/chest wall and\/or regional nodal radiotherapy in patients with breast cancer. Int J Radiat Oncol Biol Phys. 2018;100(4):871\u201384. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.12.015.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"7851_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.adro.2019.09.005","volume":"5","author":"BS Yadav","year":"2019","unstructured":"Yadav BS, Loganathan S, Sharma SC, Singh R, Dahiya D. Comparison of toxicity and cosmetic outcomes after accelerated partial breast irradiation or whole breast irradiation using 3-dimensional conformal external beam radiation therapy. Adv Radiat Oncol. 2019;5(2):171\u20139. https:\/\/doi.org\/10.1016\/j.adro.2019.09.005. PMID: 32280816; PMCID: PMC7136642","journal-title":"Adv Radiat Oncol"},{"issue":"10237","key":"7851_CR14","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","volume":"395","author":"AM Brunt","year":"2020","unstructured":"Brunt AM, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395(10237):1613\u201326.","journal-title":"Lancet"},{"issue":"5_Supplement","key":"7851_CR15","doi-asserted-by":"publisher","first-page":"GS5-12","DOI":"10.1158\/1538-7445.SABCS22-GS5-12","volume":"83","author":"BS Yadav","year":"2023","unstructured":"Yadav BS, Dahiya D, Gupta M. Hypofractionated radiotherapy in patients with breast cancer (HRBC): acute toxicity data of a phase III randomized study. Cancer Res. 2023;83(5_Supplement):GS5-12.","journal-title":"Cancer Res"},{"key":"7851_CR16","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin J, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"key":"7851_CR17","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/S1470-2045(22)00416-8","volume":"23","author":"B Yadav","year":"2022","unstructured":"Yadav B, Rana D, Bharti D, Dahiya D, Gupta A. Impact of COVID-19 pandemic on breast cancer care: report from a regional cancer centre. Lancet. 2022;23:S17.","journal-title":"Lancet"},{"issue":"1","key":"7851_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4103\/aort.aort_29_21","volume":"2","author":"A Gupta","year":"2022","unstructured":"Gupta A, Yadav BS, Gade VKV, Rana D, Bharti D, Dahiya D. Delays and disruptions in breast cancer care due to coronavirus disease-2019 pandemic: real-world data from India. Ann Oncol Res Therap. 2022;2(1):23.","journal-title":"Ann Oncol Res Therap"},{"issue":"4","key":"7851_CR19","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1053\/j.seminoncol.2015.07.002","volume":"42","author":"AG Waks","year":"2015","unstructured":"Waks AG, Lennon J, Yadav BS, Hwang H. dSchapirael Carmen M, Johnson NB, Reynolds K, Schapira L, Gilman PB, Overmoyer B. Metastasis to the cervix uteri 15 years after treatment of lobular carcinoma of the breast. Semin Oncol. 2015;42(4):e81\u201394. https:\/\/doi.org\/10.1053\/j.seminoncol.2015.07.002. Epub 2015 Jul 6. PMID: 26320072.","journal-title":"Semin Oncol"},{"issue":"2","key":"7851_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1053\/j.seminoncol.2013.01.010","volume":"40","author":"BS Yadav","year":"2013","unstructured":"Yadav BS, Bansal A, Sharma SC, Javid SH, Anderson BO, Vaklavas C, et al. A 62-year-old woman with osteogenic sarcoma in the contralateral breast 15 years after treatment for breast cancer. Semin Oncol. 2013;40(2):135\u201344. https:\/\/doi.org\/10.1053\/j.seminoncol.2013.01.010. PMID: 23540738","journal-title":"Semin Oncol"},{"key":"7851_CR21","doi-asserted-by":"publisher","unstructured":"Yadav BS, Bansal A, Das D, Thakur P, Gupta A, Dahiya D. Impact of age on outcomes in young women with breast cancer. Asia Pac J Clin Oncol. 2023. https:\/\/doi.org\/10.1111\/ajco.13945. Epub ahead of print.","DOI":"10.1111\/ajco.13945"},{"issue":"2","key":"7851_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.5603\/RPOR.a2022.0028","volume":"27","author":"BS Yadav","year":"2022","unstructured":"Yadav BS, Das D, Bansal A, Dahiya D. Hypofractionated radiotherapy in young versus older women with breast cancer: a retrospective study from India. Rep Pract Oncol Radiother. 2022;27(2):281\u201390.","journal-title":"Rep Pract Oncol Radiother"},{"issue":"4","key":"7851_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1017\/S1460396909990239","volume":"9","author":"BS Yadav","year":"2010","unstructured":"Yadav BS, Sharma SC, Menu G, et al. Pattern of care and survival in older women with breast cancer in India. J Radiother Pract. 2010;9(4):237\u201345.","journal-title":"J Radiother Pract"},{"issue":"6","key":"7851_CR24","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.4103\/jcrt.JCRT_1305_16","volume":"16","author":"BS Yadav","year":"2020","unstructured":"Yadav BS, Sharma SC, Singh R, et al. Male breast cancer: outcome with adjuvant treatment. JCRT. 2020;16(6):1287\u201393. https:\/\/doi.org\/10.4103\/jcrt.JCRT_1305_16.","journal-title":"JCRT"},{"issue":"2","key":"7851_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4103\/0973-1482.136560","volume":"10","author":"BS Yadav","year":"2014","unstructured":"Yadav BS, Sharma SC, George P, Bansal A. Post-mastectomy radiation beyond chest wall in patients with N1 breast cancer: is there a benefit? J Cancer Res Ther. 2014;10(2):279\u201383. https:\/\/doi.org\/10.4103\/0973-1482.136560.","journal-title":"J Cancer Res Ther"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07851-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07851-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07851-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T14:10:56Z","timestamp":1704204656000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07851-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["7851"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07851-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2873436\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"26 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was approved by Institute Ethics Committee wide No. PGI\/IEC\/2021\/000453 dated 30 March 2021. If there is any deviation in the protocol or modification prior, IEC approval will be taken.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}